myositis: An inflammatory disease involving a pathogenic inflammatory response in the muscle tissue.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
296 |
4. Check minimum number of eventsNone |
296 |
5. Include endpointsNone |
296 |
6. Filter based on genotype QC (FinnGen only) |
296 |
Control definitions (FinnGen only)
- Control exclude
- M13_SYSTCONNECT
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M33
- Name in latin
- Polymyositis
Similar endpoints
↥List of similar endpoints to
Polymyositis
based on the number of shared cases.
Similar with more cases:
- Dermatopolymyositis (FG)
- Dermatopolymyositis
- Systemic connective tissue disorders
- Autoimmune diseases related-to ILD
- Finngen Rheumatological endpoints
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2237 | 1327 | 876 |
| Only index persons | 1502 | 917 | 585 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.04 | 0.02 |
| Only index persons | 0.03 | 0.03 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 60.94 | 61.53 | 59.95 |
| Only index persons | 57.28 | 57.97 | 56.19 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 296 | 181 | 115 |
| Unadjusted period prevalence (%) | 0.06 | 0.06 | 0.05 |
| Median age at first event (years) | 55.49 | 55.05 | 56.19 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 271
- Matched controls
- 2712
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M33.2
ICD-10 Finland
Polymyositis
+∞
316.4
238
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
23.1
97.4
156
150
M60.9
ICD-10 Finland
Myositis, unspecified
+∞
87.3
79
*
L04AX01
ATC
azathioprine; systemic
34.6
81.0
107
50
G72.9
ICD-10 Finland
Myopathy, unspecified
116.8
59.9
63
7
L04AX03
ATC
methotrexate; systemic (immunosuppressants)
12.6
52.4
103
126
M33.9
ICD-10 Finland
Dermatopolymyositis, unspecified
+∞
46.2
43
*
H02AB06
ATC
prednisolone; systemic
7.2
45.4
216
953
M33.1
ICD-10 Finland
Other dermatomyositis
+∞
44.0
41
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
6.3
43.8
180
645
NK6QA
NOMESCO Finland
Measurement of bone density from tow or more locations with X-ray
13.1
43.4
81
85
M05BA04
ATC
alendronic acid; oral
10.2
41.1
89
124
M35.9
ICD-10 Finland
Systemic involvement of connective tissue, unspecified
+∞
37.4
35
*
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
408.9
36.9
36
*
J99.1*M33.2
ICD-10 Finland
Respiratory disorders in polymyositis
+∞
36.3
34
*
H02AB07
ATC
prednisone; oral
7.1
35.9
102
213
M60.8
ICD-10 Finland
Other myositis
395.7
35.8
35
*
P01BA02
ATC
hydroxychloroquine; oral
10.1
34.5
73
95
NJ3BG
NOMESCO Finland
MRI examination of extremities with high intensity magnet
133.4
33.5
35
*
NJ3CG
NOMESCO Finland
Extensive MRI examination of extremities with median high magnet
180.6
31.4
32
*
NXL00
NOMESCO Finland
Biopsy of muscle
90.5
29.5
32
*
L01BA01
ATC
methotrexate; systemic (folic acid analog.)
12.7
25.3
46
43
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
8.4
23.1
53
76
L04AA06
ATC
mycophenolic acid; systemic
20.3
22.9
34
19
7104A
ICD-9 Finland
Diffuse diseases of connective tissue, Polymyositis
+∞
21.1
20
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.4
20.6
162
819
71610
ICD-8 Finland
Polymyositis and dermatomyositis, Polymyositis
+∞
20.0
19
*
NGA20
NOMESCO Finland
Exploration of soft tissue knee or lower leg, open
107.6
18.8
20
*
L04AD01
ATC
ciclosporin; systemic
17.9
18.8
29
18
J84.9
ICD-10 Finland
Interstitial pulmonary disease, unspecified
23.8
18.6
26
12
J99.1
ICD-10 Finland
Respiratory disorders in other diffuse connective tissue disorders
+∞
17.9
17
*
M35.1
ICD-10 Finland
Other overlap syndromes
192.0
17.7
18
*
M35.3
ICD-10 Finland
Polymyalgia rheumatica
19.5
16.8
25
14
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
7.7
16.5
39
58
L04AA01
ATC
[U] ciclosporin; systemic
14.9
16.4
27
20
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
6.3
16.0
44
81
M05BA07
ATC
risedronic acid; oral
7.8
13.5
31
44
L88
ICPC
Rheumatoid/seropositive arthritis
7.3
13.3
32
49
J84.1
ICD-10 Finland
Other interstitial pulmonary diseases with fibrosis
17.9
13.2
20
12
M33.0
ICD-10 Finland
Juvenile dermatomyositis
+∞
12.6
12
*
G72.8
ICD-10 Finland
Other specified myopathies
11.3
12.5
23
22
L19
ICPC
Muscle symptom/complaint NOS
15.6
12.0
19
13
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
10.8
11.7
22
22
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.8
11.6
92
423
M32.9
ICD-10 Finland
Systemic lupus erythematosus, unspecified
+∞
11.5
11
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
3.9
11.3
49
146
C03CA01
ATC
furosemide; systemic
2.6
11.3
112
585
UGC12
NOMESCO Finland
Flexible bronchoscopy
4.3
11.0
42
111
TGC00
NOMESCO Finland
Bronchial lavation
9.5
11.0
22
25
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.8
10.8
48
146
R13
ICD-10 Finland
Dysphagia
4.7
10.7
37
89
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.5
10.7
105
541
L28
ICPC
Limited function/disability (L)
3.0
10.3
65
257
ZX120
NOMESCO Finland
Intravenous
3.9
10.2
43
125
JN4BD
NOMESCO Finland
Extensive body CT
3.7
10.0
45
138
R06.0
ICD-10 Finland
Dyspnoea
2.6
10.0
88
423
WYA30
NOMESCO Finland
Preparations for expected poor cooperation
4.7
9.8
33
77
R50.9
ICD-10 Finland
Fever, unspecified
3.1
9.5
56
210
A02BC02
ATC
pantoprazole; systemic
2.3
9.3
188
1348
L99
ICPC
Musculoskeletal disease other
8.2
9.3
20
26
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
4.2
9.3
35
92
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
3.6
9.3
42
130
C08CA05
ATC
nifedipine; systemic
4.6
9.1
31
74
H26.3
ICD-10 Finland
Drug-induced cataract
19.4
9.0
13
7
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.9
8.9
58
234
TPH04
NOMESCO Finland
Cathetrisation of vein
2.5
8.8
80
389
R4110
NOMESCO Finland
Physiotherapy
2.4
8.5
91
478
R4120
NOMESCO Finland
Occupational therapy
4.4
8.5
30
74
G71.9
ICD-10 Finland
Primary disorder of muscle, unspecified
92.8
8.5
9
*
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
2.6
8.4
66
296
NJ3DG
NOMESCO Finland
Very extensive MRI examination of extremities with high intensity magnet
+∞
8.4
8
*
M81.4
ICD-10 Finland
Drug-induced osteoporosis
+∞
8.4
8
*
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
3.6
8.3
38
118
XG410
NOMESCO Finland
Flow-volume spirometry
5.6
8.2
23
44
J84.8
ICD-10 Finland
Other specified interstitial pulmonary diseases
13.6
8.0
13
10
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
4.3
7.9
28
70
R4190
NOMESCO Finland
Nutritional therapy
8.0
7.5
16
21
XG466
NOMESCO Finland
Sleep oxymetry
6.6
7.4
18
29
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
4.2
7.3
27
70
G73.7*M35.0
ICD-10 Finland
Myopathy in sicca syndrome [Sjögren]
+∞
7.3
7
*
R1250
NOMESCO Finland
Evaluation of functional capability
7.7
7.3
16
22
H05AA02
ATC
teriparatide; parenteral
16.3
7.3
11
7
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
2.8
7.3
49
200
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
2.9
7.2
44
167
M62.9
ICD-10 Finland
Disorder of muscle, unspecified
30.9
7.2
9
*
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
2.3
7.2
72
365
NF1AE
NOMESCO Finland
Hip joint ultrasound examination
9.2
7.1
14
16
Z46.8
ICD-10 Finland
Fitting and adjustment of other specified devices
6.6
7.1
17
27
318
Kela drug reimbursment
Teriparatide
14.3
6.9
11
8
A28
ICPC
Limited function/disability NOS
2.6
6.8
50
215
XX9XE
NOMESCO Finland
Other ultrasound examination
17.2
6.8
10
6
AA1AD
NOMESCO Finland
CT of head and brain
2.3
6.8
73
380
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
3.3
6.8
33
109
NG4AA
NOMESCO Finland
Lower leg X-ray examination
5.8
6.7
18
33
J05AB01
ATC
aciclovir; systemic
2.3
6.7
71
366
EBA10
NOMESCO Finland
Surgical removal of tooth
3.0
6.7
38
139
N99
ICPC
Neurological disease other
12.7
6.6
11
9
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
3.1
6.5
34
118
G71.08
ICD-10 Finland
Other muscular dystrophy
71.5
6.5
7
*
M80.4
ICD-10 Finland
Drug-induced osteoporosis with pathological fracture
71.5
6.5
7
*
XA402
NOMESCO Finland
ENMG
5.8
6.4
17
31
M79.1
ICD-10 Finland
Myalgia
2.7
6.3
43
176
QBA99
NOMESCO Finland
Other local destruction of skin of trunk
18.5
6.3
9
5
M60.0
ICD-10 Finland
Infective myositis
+∞
6.3
6
*
J99.1*M33.9
ICD-10 Finland
Respiratory disorders in dermatopolymyositis
+∞
6.3
6
*
NA3AD
NOMESCO Finland
Lumbar spine and sacrum CT examination
6.5
6.3
15
24
N28
ICPC
Limited function/disability (N)
8.0
6.2
13
17
Z50.1
ICD-10 Finland
Other physical therapy
3.7
6.1
25
72
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
94
12
114.32
181.76
4.1
1.2
9.3
5.4
u/l
1.79
89
12
49
11
53.18
84.05
1.2
1.0
—
—
—
0
0
53
42
15.15
56.11
1.8
1.2
51.3
—
u/ml
—
8
0
47
53
10.35
39.16
1.6
1.2
3.6
3.1
u/ml
—
18
6
50
64
9.20
37.80
2.1
1.3
—
—
—
0
0
41
59
7.91
27.89
1.5
1.6
—
0.0
—
0
7
23
18
13.77
23.99
1.3
1.2
—
—
—
0
0
23
18
13.77
23.99
1.3
1.2
—
—
—
0
0
23
19
13.04
23.23
1.3
1.2
—
—
—
0
0
23
19
13.04
23.23
1.3
1.2
—
—
—
0
0
23
19
13.04
23.23
1.3
1.2
—
—
—
0
0
226
1347
3.87
23.10
20.4
9.1
4.4
4.1
e9/l
0.97
218
1181
197
1149
3.14
19.36
14.2
6.6
1.2
1.2
mmol/l
0.60
174
976
187
1063
3.06
19.18
12.3
5.5
1.2
1.2
mmol/l
1.03
178
955
89
358
3.12
16.64
2.4
1.8
—
—
—
0
0
26
44
6.38
15.06
11.3
8.0
189.1
144.3
iu/ml
—
7
8
16
16
10.51
14.14
1.4
1.2
2.2
—
u/ml
—
5
0
53
170
3.58
14.13
4.8
3.5
189.2
191.3
ng/l
0.02
47
159
28
55
5.52
13.93
1.7
1.8
—
—
—
0
0
16
17
9.89
13.55
1.6
1.2
133.7
—
u/ml
—
6
0
243
1758
3.13
13.49
13.1
3.8
15.6
12.2
mm/h
3.02
237
1608
159
942
2.49
13.28
3.1
2.2
80.3
77.8
nmol/l
0.50
152
833
28
60
5.05
12.64
1.8
1.7
—
—
—
0
0
129
709
2.45
12.53
4.9
3.1
1160.8
1192.6
ng/l
0.04
118
605
65
254
3.00
12.48
2.3
1.7
—
—
—
0
0
49
166
3.34
11.93
2.4
1.5
—
—
—
0
0
33
86
4.19
11.73
3.0
2.7
—
—
—
0
0
31
77
4.38
11.72
2.0
2.3
3.2
3.1
g/l
0.12
24
64
25
52
5.16
11.66
1.3
1.2
—
—
—
0
0
31
78
4.32
11.52
2.0
2.2
9.7
9.8
g/l
0.04
25
71
20
34
6.24
11.48
1.7
1.4
—
—
—
0
0
163
1024
2.32
11.33
7.5
4.2
33.9
35.6
g/l
2.85
158
964
32
84
4.15
11.26
1.9
2.2
3.3
3.8
g/l
1.99
23
62
32
84
4.15
11.26
1.9
2.2
—
—
—
0
0
32
84
4.15
11.26
1.9
2.2
7.3
7.4
g/l
0.06
25
66
18
28
6.78
11.22
2.3
1.8
—
—
—
0
0
20
36
5.89
10.85
1.3
1.3
—
—
—
0
0
19
34
5.90
10.36
1.3
1.2
224.4
236.0
u/ml
0.05
13
20
60
251
2.74
10.03
2.3
1.7
—
—
—
0
0
170
1135
2.17
9.60
5.6
3.6
0.0
0.0
estimate
0.00
30
209
21
45
4.95
9.45
1.5
1.6
—
—
—
0
0
183
1264
2.17
9.39
9.0
6.2
10.3
11.2
umol/l
0.90
177
1188
13
17
7.95
9.35
1.1
1.1
—
—
—
0
0
127
764
2.16
9.31
6.0
3.0
49.4
31.6
u/l
1.97
122
726
113
656
2.17
9.01
4.6
3.0
0.4
0.3
e6/l
0.11
88
476
21
47
4.73
8.99
1.7
1.8
—
—
—
0
0
12
15
8.30
8.92
2.3
1.1
—
—
—
0
0
87
464
2.24
8.49
6.4
3.7
210.3
195.5
ng/l
0.04
79
375
167
1143
2.06
8.42
7.7
4.9
0.0
0.0
estimate
0.00
34
210
13
9
15.03
8.28
1.9
2.1
—
—
—
0
0
57
256
2.52
8.18
17.8
6.9
5.3
5.1
kpa
0.65
52
244
57
256
2.52
8.18
17.7
6.9
10.4
12.2
kpa
2.44
52
246
11
14
8.12
8.04
1.1
1.2
—
—
—
0
0
167
1157
2.02
7.99
5.7
3.7
0.0
0.0
estimate
0.00
35
202
64
310
2.36
7.77
3.1
2.3
22.1
22.7
%
0.13
52
268
14
25
5.83
7.61
1.9
2.0
—
—
—
0
0
56
260
2.42
7.45
18.1
6.9
2.0
1.2
mmol/l
0.49
46
208
77
410
2.19
7.44
3.6
2.6
0.7
1.2
e6/l
1.56
46
233
14
26
5.60
7.32
1.1
1.1
—
—
—
0
0
13
23
5.87
7.13
1.8
2.1
—
—
—
0
0
17
39
4.56
7.05
1.6
1.6
—
—
—
0
0
43
181
2.61
7.01
19.3
7.1
11.1
9.7
mmol/l
0.44
43
174
45
197
2.51
6.77
3.2
2.2
18.3
7.2
ug/l
2.02
39
174
16
37
4.51
6.57
1.1
1.6
—
—
—
0
0
55
268
2.29
6.53
2.5
2.6
7.2
9.4
umol/l
0.53
44
236
70
379
2.11
6.40
4.1
2.8
2.7
2.7
e6/l
0.00
41
205
15
34
4.59
6.31
1.1
1.6
—
—
—
0
0
97
597
1.93
6.18
4.1
2.7
374.9
8984.9
umol/l
3.30
91
510
86
509
1.97
6.14
1.2
1.2
1.0
1.3
u/ml
0.24
17
149
71
393
2.06
6.10
1.5
1.2
62.8
41.7
iu/ml
0.35
27
125
13
28
4.81
5.79
1.4
1.3
—
—
—
0
0
14
33
4.40
5.62
1.9
1.7
—
—
—
0
0
15
38
4.10
5.51
1.7
1.6
—
—
—
0
0
16
44
3.79
5.28
1.5
1.3
—
—
—
0
0
16
44
3.79
5.28
1.5
1.3
—
—
—
0
0
14
36
4.03
5.04
5.2
2.8
5.2
4.9
e9/l
0.16
14
36
31
131
2.53
5.01
1.5
1.4
—
—
—
0
0
84
525
1.84
4.96
2.3
1.7
1.3
1.2
mg/l
0.16
67
422
14
37
3.92
4.87
5.6
3.4
65.7
61.1
%
0.70
14
37
22
79
2.93
4.83
1.4
1.2
—
—
—
0
0
86
546
1.81
4.81
2.7
2.0
3.0
3.2
mg/l
0.39
76
471
22
80
2.89
4.73
1.4
1.2
—
—
—
0
0
44
223
2.14
4.71
2.3
2.3
518.7
33.0
u/l
0.49
37
187
176
1376
1.69
4.57
11.2
4.4
6.5
6.7
mmol/l
1.23
166
1283
10
21
4.89
4.56
1.5
1.9
—
—
—
0
0
10
21
4.89
4.56
1.5
1.9
—
—
—
0
0
10
21
4.89
4.56
1.5
1.9
—
—
—
0
0
108
746
1.70
4.46
2.9
2.4
53.8
55.0
u/l
0.17
102
680
115
815
1.67
4.28
4.1
3.3
2.3
2.4
mmol/l
1.12
104
712
71
441
1.80
4.22
1.7
1.7
1151.8
1180.3
nmol/l
0.09
56
326
131
967
1.64
4.12
2.1
2.0
95.8
95.0
pmol/l
0.06
73
479
87
578
1.72
4.09
1.6
1.5
20.5
21.6
nmol/l
0.33
76
484
19
70
2.83
4.00
1.7
1.2
—
—
—
0
0
62
378
1.81
3.90
1.3
1.2
53.0
11.3
u/ml
0.68
18
145
129
959
1.61
3.88
3.4
2.6
165.9
114.5
ug/l
1.17
121
882
27
121
2.36
3.87
1.4
1.3
—
—
—
0
0
29
135
2.27
3.82
2.1
1.6
—
—
—
0
0
6
5
12.21
3.78
1.2
1.0
—
—
—
0
0
21
86
2.55
3.64
2.8
1.9
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
17
63
2.80
3.55
5.5
2.1
0.3
0.3
u/ml
—
10
29
8
13
6.29
3.52
1.8
1.5
—
—
—
0
0
124
938
1.55
3.34
5.4
3.6
91.1
31.5
ng/l
3.13
102
658
15
54
2.87
3.30
2.1
1.3
—
—
—
0
0
13
44
3.04
3.17
1.4
1.4
—
—
—
0
0
8
16
5.11
3.07
1.0
1.0
—
—
—
0
0
15
57
2.72
3.01
1.3
1.3
—
—
—
0
0
5
5
10.14
2.99
1.0
1.2
—
—
—
0
0
6
9
6.78
2.88
1.0
1.1
—
—
—
0
0
69
470
1.61
2.86
2.4
2.9
2.5
2.5
mmol/l
0.13
58
415
48
300
1.72
2.76
24.5
21.0
2.2
1.3
inr
—
5
38
6
10
6.10
2.71
1.8
2.1
—
—
—
0
0
6
10
6.10
2.71
1.8
2.1
—
—
—
0
0
6
10
6.10
2.71
1.8
2.1
—
—
—
0
0
7
15
4.75
2.61
1.7
1.7
—
—
—
0
0
7
15
4.75
2.61
1.7
1.7
—
—
—
0
0
7
15
4.75
2.61
2.1
2.9
972.4
739.6
u/ml
—
7
15
7
15
4.75
2.61
1.7
1.7
—
—
—
0
0
7
15
4.75
2.61
1.7
1.7
—
—
—
0
0
256
2343
1.69
2.46
35.6
13.4
20.2
23.6
mg/l
1.37
244
1831
10
34
3.01
2.43
1.2
1.1
—
—
—
0
0
201
2241
0.68
2.41
4.7
4.1
1.7
1.3
mmol/l
3.74
189
2043
13
53
2.52
2.31
1.1
1.1
—
—
—
0
0
17
79
2.22
2.29
2.6
1.7
—
—
—
0
0
8
23
3.54
2.28
1.1
1.0
—
—
—
0
0
5
9
5.63
2.22
1.0
1.1
—
—
—
0
0
179
1540
1.41
2.18
4.2
3.0
51.3
49.2
u/l
0.17
173
1428
9
30
3.06
2.16
1.0
1.1
—
—
—
0
0
7
19
3.75
2.16
1.3
1.2
—
—
—
0
0
6
14
4.35
2.16
1.3
1.5
1.0
1.0
g/l
—
6
14
6
14
4.35
2.16
1.5
1.1
—
—
—
0
0
212
2325
0.69
2.11
5.0
4.5
1.3
1.5
mmol/l
6.34
201
2140
7
20
3.56
2.06
1.0
1.0
—
—
—
0
0
13
57
2.34
2.00
1.3
1.7
—
—
—
0
0
5
11
4.60
1.95
4.2
2.0
48.2
59.2
ug/l
—
5
11
7
22
3.23
1.89
1.3
1.5
—
—
—
0
0
67
495
1.46
1.89
7.1
3.9
1.0
1.0
kg/l
0.26
12
72
11
46
2.45
1.87
4.5
2.6
15.2
16.5
%
—
5
23
6
17
3.58
1.84
1.3
3.6
—
—
—
0
0
12
54
2.27
1.76
3.3
2.1
114.0
132.1
g/l
—
7
37
6
18
3.38
1.75
1.0
1.2
—
—
—
0
0
9
36
2.55
1.75
1.1
1.1
—
—
—
0
0
216
2339
0.72
1.71
5.0
4.6
4.8
4.7
mmol/l
0.64
204
2162
9
189
0.46
1.68
2.1
1.8
—
—
—
0
0
6
19
3.20
1.67
2.7
2.4
—
—
—
0
0
11
49
2.29
1.65
1.1
1.3
—
—
—
0
0
37
249
1.56
1.62
6.2
3.4
—
—
—
0
0
6
20
3.04
1.59
1.0
1.1
—
—
—
0
0
198
1781
1.34
1.55
4.7
4.0
15.2
14.8
pmol/l
1.68
185
1600
8
33
2.46
1.55
1.4
1.2
—
—
—
0
0
28
179
1.62
1.52
7.1
2.6
4.8
4.4
kpa
0.67
28
172
5
16
3.16
1.44
1.2
1.5
—
—
—
0
0
5
16
3.16
1.44
1.2
1.5
—
—
—
0
0
223
2378
0.75
1.31
5.4
5.2
2.9
2.8
mmol/l
1.10
213
2183
6
25
2.43
1.25
2.2
1.6
—
—
—
0
0
6
25
2.43
1.25
2.2
1.6
—
—
—
0
0
5
19
2.66
1.22
1.2
1.5
—
—
—
0
0
106
899
1.28
1.21
6.2
3.7
—
—
—
0
0
77
626
1.31
1.21
7.2
3.8
0.0
0.0
estimate
0.00
34
206
6
26
2.33
1.19
2.2
1.6
—
—
—
0
0
6
26
2.33
1.19
2.2
1.6
—
—
—
0
0
6
26
2.33
1.19
2.2
1.6
—
—
—
0
0
6
26
2.33
1.19
2.2
1.6
—
—
—
0
0
11
57
1.97
1.18
1.2
1.3
—
—
—
0
0
7
30
2.36
1.13
1.1
1.0
—
—
—
0
0
18
112
1.65
1.11
1.0
1.0
—
—
—
0
0
12
66
1.85
1.10
2.3
1.4
—
—
—
0
0
124
1085
1.25
1.06
5.6
3.8
—
—
—
0
0
9
49
1.86
0.99
1.8
1.5
—
—
—
0
0
6
27
2.25
0.94
4.3
3.7
—
—
—
0
0
6
29
2.09
0.90
1.2
1.3
—
—
—
0
0
10
164
0.60
0.83
1.6
1.7
—
—
—
0
0
65
549
1.24
0.75
3.2
2.2
—
—
—
0
0
35
277
1.30
0.69
1.4
1.7
1.4
1.5
%
0.72
28
240
0
21
0.00
0.60
0.0
1.1
—
—
—
0
0
0
23
0.00
0.58
0.0
1.4
—
—
—
0
0
0
23
0.00
0.58
0.0
1.4
—
—
—
0
0
0
23
0.00
0.58
0.0
1.4
—
—
—
0
0
26
204
1.30
0.56
3.0
2.9
82.4
62.5
ml/min/173m2
—
8
83
6
37
1.63
0.56
2.2
2.7
—
9.9
—
0
8
9
60
1.52
0.55
1.7
1.3
—
—
—
0
0
224
2151
1.17
0.53
5.7
4.8
1.9
2.5
mu/l
0.50
215
1937
9
63
1.44
0.53
3.8
2.3
24.5
24.9
mmol/l
—
9
52
73
651
1.16
0.49
1.6
1.6
1.7
1.3
mmol/l
2.17
65
552
215
2230
0.87
0.47
6.4
5.8
40.1
40.0
mmol/mol
0.08
204
2064
10
69
1.46
0.45
1.7
1.6
—
—
—
0
0
8
57
1.41
0.42
1.8
1.8
—
—
—
0
0
41
353
1.19
0.42
1.4
1.4
—
—
—
0
0
0
16
0.00
0.41
0.0
3.7
—
—
—
0
0
45
402
1.14
0.31
2.8
3.0
0.7
0.8
ug/l
0.36
33
264
15
182
0.81
0.27
1.4
1.8
—
—
—
0
0
5
42
1.19
0.21
1.2
1.4
—
—
—
0
0
8
104
0.76
0.21
3.1
3.4
10.3
1467.8
u/ml
—
8
89
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
227
2306
0.93
0.16
5.2
4.6
5.8
6.0
mmol/l
1.71
208
2117
140
1359
1.06
0.16
3.1
2.8
—
—
—
0
0
207
2104
0.95
0.14
41.8
14.6
39.6
39.8
%
0.08
141
1503
33
355
0.92
0.13
2.0
1.4
—
—
—
0
0
33
308
1.08
0.12
4.5
4.3
28.1
31.7
%
1.24
25
190
71
683
1.05
0.11
4.7
4.7
4.0
2.2
ug/l
0.56
65
612
8
76
1.05
0.07
1.0
1.7
—
—
—
0
0
30
292
1.03
0.02
7.6
6.5
—
—
—
0
0
54
547
0.98
0.01
3.6
4.3
21.4
21.4
%
0.02
26
256
224
2234
1.01
0.00
28.2
13.0
86.5
79.9
ml/min/173m2
3.55
203
1824
15
148
1.01
0.00
2.1
2.4
11.2
13.9
nmol/l
1.11
15
137
0
6
0.00
0.00
0.0
2.0
—
1.2
—
0
6
5
58
0.86
0.00
1.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint M13_POLYMYO and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_POLYMYO | 2.097 [1.76, 2.5] | < 0.001 |
| Birth year | 0.994 [0.99, 1.0] | 0.186 |
During the follow-up period (1.1.1998 — 31.12.2019), 247 out of 750 females with M13_POLYMYO died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_POLYMYO | 2.472 [2.02, 3.03] | < 0.001 |
| Birth year | 0.987 [0.98, 1.0] | 0.006 |
During the follow-up period (1.1.1998 — 31.12.2019), 217 out of 521 males with M13_POLYMYO died.
Mortality risk
Mortality risk for people of age
years, who have M13_POLYMYO.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.119% | 0.47% |
| 5 | 1.131% | 2.714% |
| 10 | 2.947% | 6.901% |
| 15 | 5.887% | 13.095% |
| 20 | 10.067% | 21.454% |
Relationships between endpoints
↥Index endpoint: M13_POLYMYO – Polymyositis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data